OvaScience

OvaScience

Based: Boston
Raised: $38.56 million
Investors: Cycad Group, General Catalyst Partners, Hunt BioVentures, Longwood Founders Management, RA Capital Management, undisclosed investor

The scoop: At Sirtris Pharmaceuticals, Michelle Dipp played a key role in positioning the company for a $720 million sale to GlaxoSmithKline. Now as CEO of OvaScience, she has a big B round to advance work on stem cell technology for new fertility treatments. By taking mitochondria from a woman's ovarian stem cells and then inserting them - along with sperm - into eggs, OvaScience believes it can significantly improve the success rate for in vitro fertilization. The lead therapy is headed to the clinic later this year.

OvaScience
Read more on

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.